First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors

被引：0
|
作者：
Daud, Adil
Albany, Costantine
Velcheti, Vamsidhar
Hauke, Ralph J.
Ahnert, Jordi Rodon
Karp, Daniel D.
Tsimberidou, Apostolia Maria
Cohen, Julia Wanda
Schmidt, Emmett V.
Wang, Jieyi
Chan, C. Hubert
Fu, Siqing
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Horizon Oncol & Res Ctr, Lafayette, IN USA
[3] NYU, New York, NY USA
[4] Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[5] Nebraska Canc Specialists, Omaha, NE USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Merck Co Inc, Rahway, NJ USA
[8] Lyvgen Biopharma, Shanghai, Peoples R China
[9] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2525
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma
    Tolcher, Anthony
    Karim, Raghad
    Rosas, Christina
    Liu, Guizhong
    Zhu, Yi
    Liu, Liming
    Du, Felix Fangyong
    Luo, Feng Roger
    Luo, Peter
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [22] A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors
    Barve, Minal A.
    Tolcher, Anthony W.
    Carvajal, Richard D.
    Izar, Benjamin
    El-Khoueiry, Anthony B.
    Hanna, Diana L.
    Tarhini, Ahmad A.
    Whitman, Eric D.
    Bhatia, Shailender
    Davar, Diwakar
    Lutzky, Jose
    Taylor, Matthew H.
    Tello, Monique
    Rosenthal, Katherine
    Danielyan, Anna
    Yip, Wai Ki
    Song, James
    Chand, Dhan
    Grossman, Joseph Elan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
    Frentzas, Sophia
    Gan, Hui K.
    Cosman, Rasha
    Coward, Jermaine
    Tran, Ben
    Millward, Michael
    Zhou, Yiting
    Wang, Wenjing
    Xia, Dennis
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Michelle
    Desai, Jayesh
    CELL REPORTS MEDICINE, 2023, 4 (11)
  • [24] Anti-human 4-1BB ligand monoclonal antibody (clone1F1) or anti-human CD137 ligand monoclonal antibody (clone1F1)
    Zhang, XG
    HYBRIDOMA AND HYBRIDOMICS, 2003, 22 (06): : 407 - 407
  • [25] Preclinical investigations and a first-in-human phase 1a trial of JS']JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors
    Zhou, Chenfei
    Jiang, Jinling
    Xiang, Xiaojun
    Liu, Hongli
    Wu, Guowu
    Zeng, Ruichao
    Lu, Tong
    Zhang, Mengqi
    Shen, Yuteng
    Hong, Min
    Zhang, Jun
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [26] A first-in-human Phase 1 study of anti-CD105 antibody therapy with TRC105 in patients with advanced solid tumors
    Rosen, L.
    Gordon, M. S.
    Hurwitz, H. I.
    Wong, M. K.
    Goldman, J.
    Adams, B. J.
    Alvarez, D.
    Seon, B. K.
    Theuer, C. P.
    Leigh, B. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 116 - 116
  • [27] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [28] Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
    Ullenhag, Gustav J.
    Carneiro, Ana
    Smith, Karin Enell
    Schultz, Lena
    Ambarkhane, Sumeet Vijay
    Landstrom, Tova
    Yachnin, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors
    Papadopoulos, Kyriakos P.
    Borazanci, Erkut
    Von Hoff, Daniel
    Gandhi, Leena
    Patnaik, Amita
    Tachibana, Masaya
    Zahir, Hamim
    Gajee, Roohi
    Goldberg, Tern
    Senaldi, Giorgio
    Ou, Sai-Hong
    CANCER RESEARCH, 2016, 76
  • [30] Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors
    Saeed, Anwaar
    Bashir, Babar
    Luke, Jason J.
    Chantre, Reuven
    Amsili, Shira
    Tabakman, Rinat
    Shwartz, Yaffa
    Foley-Comer, Adam
    Jimeno, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345